ATAI
AtaiBeckley Inc.
$3.92
+3.16%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders50 funds
Inst. Value$177.0M
Inst. Activity3 buys / 1 sells
Insider Activity0B / 2S
Insider Net $-$567.9K
Reddit Sentiment70° Bullish
SEC Reports3
Press Releases6
Recent Activity
Jun 11, 2026
short_volume
Short Volume: ATAI — 73.3% short (1.6M / 2.2M)
Short: 1,589,723 | Exempt: 13,226 | TRF Vol: 2,168,714 | Short Ratio: 73.3% | Off-exchange volume (d
Jun 4, 2026
Insider
Fischer Laurent was granted 121,968 shares
Director
Jun 4, 2026
Insider
JOHNSON SABRINA MARTUCCI was granted 121,968 shares
Director
Jun 4, 2026
Insider
Kalali Amir H was granted 121,968 shares
Director
Jun 3, 2026
SEC
AtaiBeckley filed an 8-K announcing management's participation in four investor conferences in June 2026, including the
8-K — Impact 2/10
May 12, 2026
SEC
AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K, well above the $91
PRESS-RELEASE — Impact 5/10
Apr 20, 2026
SEC
Craig Kevin James, an officer of AtaiBeckley Inc., filed a Form 144 to notify the SEC of his intent to sell up to 42,579
144 — Impact 3/10
Inst.
BlackRock, Inc. — NEW
6,835,300 shares ($24.2M)
Price Targets
$14.00
+257.1% upside
Strong Buy
Current $3.92
Low $7.00
Median $14.50
High $25.00
12 analysts
$7.00
$25.00
Analyst Ratings
5Strong Buy
14Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 17, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | Deutsche Bank | INITIATE | Buy |
| Mar 17, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▲ +8.2% | $-0.21 — $-0.08 | 18% YoY | 8 |
| Next Q | $-0.12 ▲ +8.7% | $-0.21 — $-0.08 | 56% YoY | 8 |
| Current FY | $-0.44 ▲ +9.3% | $-0.74 — $-0.33 | 85% YoY | 9 |
| Next FY | $-0.46 ▲ +6.3% | $-0.60 — $-0.40 | -3% YoY | 7 |
Latest Reports
NEUTRAL
8-K
2/10
AtaiBeckley filed an 8-K announcing management's participation in four investor conferences in June 2026, including the
Jun 3, 2026
MIXED
PRESS-RELEASE
5/10
AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K, well above the $91
May 12, 2026
NEUTRAL
Press
3/10
AtaiBeckley Inc. received the Silver Award in OVID Health’s 2026 Patient Participant Index for its collaboration with th
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $41.6M | — |
| BlackRock, Inc. | $24.2M | NEW |
| ADAGE CAPITAL PARTNERS GP, | $20.0M | NEW |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.7M | — |
| MORGAN STANLEY | $13.6M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Fischer Laurent | A | $0.00 |
| Jun 4, 2026 | JOHNSON SABRINA | A | $0.00 |
| Jun 4, 2026 | Kalali Amir | A | $0.00 |
| Jun 4, 2026 | Smiley Andrea | A | $0.00 |
| Jun 4, 2026 | HERSHBERG ROBERT | A | $0.00 |
Reddit Sentiment
70°▲
Bullish
Bearish
Neutral
Bullish
50 institutional holders with $177.0M total value (50,006,642 shares) as of 2026-Q1. Top holders: VANGUARD, BlackRock,, ADAGE. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 11,761,398 | $41.6M | 23.5% | — |
| 2 | BlackRock, Inc. | 6,835,300 | $24.2M | 13.7% | NEW |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,642,758 | $20.0M | 11.3% | NEW |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 5,286,326 | $18.7M | 10.6% | — |
| 5 | MORGAN STANLEY | 3,852,772 | $13.6M | 7.7% | NEW |
| 6 | MARSHALL WACE, LLP | 2,364,446 | $8.4M | 4.7% | NEW |
| 7 | RTW INVESTMENTS, LP | 2,000,000 | $7.1M | 4.0% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 1,975,552 | $7.0M | 4.0% | — |
| 9 | VANGUARD FIDUCIARY TRUST CO | 1,256,731 | $4.4M | 2.5% | — |
| 10 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,181,583 | $4.2M | 2.4% | — |
| 11 | STATE STREET CORP | 1,144,355 | $4.1M | 2.3% | — |
| 12 | BANK OF AMERICA CORP /DE/ | 819,664 | $2.9M | 1.6% | — |
| 13 | Point72 Asset Management, L.P. | 664,724 | $2.4M | 1.3% | — |
| 14 | Woodline Partners LP | 600,000 | $2.1M | 1.2% | — |
| 15 | Sumitomo Mitsui Trust Group, Inc. | 567,576 | $2.0M | 1.1% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 547,200 | $1.9M | 1.1% | — |
| 17 | GOLDMAN SACHS GROUP INC | 520,905 | $1.8M | 1.0% | — |
| 18 | CITADEL ADVISORS LLC | 261,200 | $924.6K | 0.5% | — |
| 19 | Jain Global LLC | 244,187 | $864.4K | 0.5% | — |
| 20 | Brevan Howard Capital Management LP | 236,942 | $838.8K | 0.5% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | NEW | — | 6,835,300 | — | $24.2M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 5,642,758 | — | $20.0M | 2026-Q1 |
| MORGAN STANLEY | NEW | — | 3,852,772 | — | $13.6M | 2026-Q1 |
| ARK Investment Management LLC | EXIT | 3,305,997 | 0 | -100.0% | $0.00 | 2026-Q1 |
| ARK Investment Management LLC | NEW | — | 3,305,997 | — | $13.5M | 2025-Q4 |
| MARSHALL WACE, LLP | NEW | — | 2,675,117 | — | $10.9M | 2025-Q4 |
15 unique insiders with 27 transactions. Net insider value: -$567.9K ($0.00 bought, $567.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Fischer Laurent | Director | AWARD | 121,968 | — | — |
| Jun 4, 2026 | JOHNSON SABRINA MARTUCCI | Director | AWARD | 121,968 | — | — |
| Jun 4, 2026 | Kalali Amir H | Director | AWARD | 121,968 | — | — |
| Jun 4, 2026 | Smiley Andrea Heslin | Director | AWARD | 121,968 | — | — |
| Jun 4, 2026 | HERSHBERG ROBERT | Director | AWARD | 121,968 | — | — |
| Jun 4, 2026 | Braunstein Scott | Director | AWARD | 121,968 | — | — |
| Jun 4, 2026 | Hoffman John Francis | Director | AWARD | 121,968 | — | — |
| Jun 4, 2026 | Angermayer Christian | Director | AWARD | 121,968 | — | — |
| Apr 20, 2026 | Craig Kevin James | Chief Medical Officer | EXERCISE | 27,280 | $1.50 | $40.9K |
| Apr 20, 2026 | Craig Kevin James | Chief Medical Officer | SELL | 42,579 | $5.00 | $212.9K |
| Apr 8, 2026 | Angermayer Christian | Director | EXERCISE | 46,070 | $1.88 | $86.6K |
| Mar 20, 2026 | Craig Kevin James | Chief Medical Officer | EXERCISE | 76,224 | $1.18 | $89.9K |
| Mar 20, 2026 | Craig Kevin James | Chief Medical Officer | SELL | 100,000 | $3.55 | $355.0K |
| Mar 11, 2026 | Faerm Michael E. | Chief Financial Officer | AWARD | 285,000 | — | — |
| Mar 11, 2026 | Faerm Michael E. | Chief Financial Officer | AWARD | 1,275,000 | — | — |
| Jan 30, 2026 | Kochendoerfer Gerd | Chief Operating Officer | AWARD | 675,000 | — | — |
| Jan 30, 2026 | Kochendoerfer Gerd | Chief Operating Officer | AWARD | 150,000 | — | — |
| Jan 30, 2026 | Rao Srinivas | See remarks | AWARD | 1,988,000 | — | — |
| Jan 30, 2026 | Rao Srinivas | See remarks | AWARD | 442,000 | — | — |
| Jan 30, 2026 | Barrett Christopher Ryan Cave | See remarks | AWARD | 675,000 | — | — |
| Jan 30, 2026 | Barrett Christopher Ryan Cave | See remarks | AWARD | 150,000 | — | — |
| Jan 30, 2026 | Johnson Anne Nagengast | Chief Financial Officer | AWARD | 525,000 | — | — |
| Jan 30, 2026 | Johnson Anne Nagengast | Chief Financial Officer | AWARD | 117,000 | — | — |
| Jan 30, 2026 | Short Glenn Frank | Chief Scientific Officer | AWARD | 675,000 | — | — |
| Jan 30, 2026 | Short Glenn Frank | Chief Scientific Officer | AWARD | 150,000 | — | — |
| Jan 30, 2026 | Craig Kevin James | Chief Medical Officer | AWARD | 675,000 | — | — |
| Jan 30, 2026 | Craig Kevin James | Chief Medical Officer | AWARD | 150,000 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.3/10.
NEUTRAL
8-K
2/10
AtaiBeckley filed an 8-K announcing management's participation in four investor conferences in June
Jun 3, 2026
MIXED
PRESS-RELEASE
5/10
AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K
May 12, 2026
NEUTRAL
144
3/10
Craig Kevin James, an officer of AtaiBeckley Inc., filed a Form 144 to notify the SEC of his intent
Apr 20, 2026
NEUTRAL
3/10
AtaiBeckley Inc. received the Silver Award in OVID Health’s 2026 Patient Participant Index for its c
Apr 27, 2026
BULLISH
8/10
AtaiBeckley announced positive Phase 2a results for BPL-003 in treatment-resistant depression, showi
Apr 8, 2026
NEUTRAL
5/10
AtaiBeckley Inc. (ATAI) was added to the S&P Total Market Index, S&P Completion Index, and CRSP U.S.
Mar 24, 2026
BULLISH
8/10
AtaiBeckley Inc. announced the peer-reviewed publication of positive Phase 2a data for its intranasa
Mar 17, 2026
BULLISH
8/10
AtaiBeckley Inc. announced progress in advancing its lead candidate BPL-003 into Phase 3 trials for
Mar 10, 2026
MIXED
6/10
AtaiBeckley Inc. reported its Q4 and full-year 2025 financial results, highlighted by a successful F
Mar 6, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 5 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.00 mean target
+257.1% upside
Strong Buy (1.14)
$7.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $3.92 |
| Target Low | $7.00 |
| Target Mean | $14.00 |
| Target Median | $14.50 |
| Target High | $25.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.21 | $-0.08 | 18.3% | +8.2% | 3↑ 2↓ | $0.0B | -88.4% | 8 |
| Next Q 2026-09-30 |
$-0.12 | $-0.21 | $-0.08 | 56.3% | +8.7% | 2↑ 2↓ | $0.0B | -88.9% | 8 |
| Current FY 2026-12-31 |
$-0.44 | $-0.74 | $-0.33 | 84.9% | +9.3% | 3↑ 3↓ | $0.0B | -72.9% | 9 |
| Next FY 2027-12-31 |
$-0.46 | $-0.60 | $-0.40 | -3.4% | +6.3% | 1↑ 4↓ | $0.0B | -73.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.114 | |
| 7d ago | $-0.112 | -0.003 |
| 30d ago | $-0.125 | +0.010 |
| 60d ago | $-0.125 | +0.010 |
| 90d ago | $-0.125 | +0.011 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Deutsche Bank | INITIATE | — | Buy |
| Mar 17, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 9, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Guggenheim | INITIATE | — | Buy |
| Dec 23, 2025 | Jones Trading | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 5 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 5 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 4 | 13 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
70°
Bullish
Bearish
Neutral
Bullish
18 mentions
11 bullish
2 bearish
15 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Feb 27, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Feb 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 18, 2026 | 3 | 57° Neutral | 1 | 0 | 3 |
| Feb 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 9, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
5 Penny Stocks That Might Be About to Take Off
▲ 1
💬 1
⚡ 0.5
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
▲ 1
💬 1
⚡ 0.5
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
▲ 1
💬 0
⚡ 0.5
Here’s what $ATAI is actually building🧬
▲ 1
💬 1
⚡ 0.5
$ATAI isn’t just biotech noise
▲ 1
💬 1
⚡ 0.5
Recent update on $ATAI
▲ 1
💬 1
⚡ 0.0
Update on $ATAI
▲ 1
💬 1
⚡ 0.0
Recent update from $ATAI
▲ 1
💬 0
⚡ 0.0
Recent update on $ATAI
▲ 1
💬 0
⚡ 0.0
Recent update on $ATAI
▲ 1
💬 0
⚡ 0.0
$ATAI and the new approach to curing depression
▲ 13
💬 2
⚡ 0.0
AtaiBeckley $ATAI Provides Update and Outlook for 2026
▲ 5
💬 4
⚡ 0.0
Jun 11, 2026
short_volume
Short Volume: ATAI — 73.3% short (1.6M / 2.2M)
Short: 1,589,723 | Exempt: 13,226 | TRF Vol: 2,168,714 | Short Ratio: 73.3% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: ATAI — 56.1% short (0.7M / 1.3M)
Short: 740,518 | Exempt: 4,995 | TRF Vol: 1,319,401 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: ATAI — 57.7% short (1.2M / 2.1M)
Short: 1,186,002 | Exempt: 2,093 | TRF Vol: 2,057,069 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ATAI — 58.8% short (1.6M / 2.7M)
Short: 1,562,517 | Exempt: 2,478 | TRF Vol: 2,658,265 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: ATAI — 57.6% short (1.1M / 1.8M)
Short: 1,054,805 | Exempt: 56,486 | TRF Vol: 1,832,183 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: ATAI — 55.9% short (1.2M / 2.1M)
Short: 1,186,537 | Exempt: 4,800 | TRF Vol: 2,120,974 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
<p>NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company o
May 19, 2026
short_volume
Short Volume: ATAI — 64.3% short (1.3M / 2.1M)
Short: 1,332,306 | Exempt: 2,938 | TRF Vol: 2,070,599 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ATAI — 56.0% short (0.8M / 1.5M)
Short: 818,155 | Exempt: 1,805 | TRF Vol: 1,460,018 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
<p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotech
May 12, 2026
short_volume
Short Volume: ATAI — 56.6% short (1.4M / 2.4M)
Short: 1,375,232 | Exempt: 46,771 | TRF Vol: 2,431,137 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
ATAI Q1 2026 Earnings Scheduled — 2026-05-11
May 5, 2026
short_volume
Short Volume: ATAI — 59.9% short (1.2M / 2.0M)
Short: 1,195,846 | Exempt: 3,189 | TRF Vol: 1,996,550 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: ATAI — 65.9% short (2.2M / 3.4M)
Short: 2,221,830 | Exempt: 2,209 | TRF Vol: 3,369,159 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
May 1, 2026
Clinical Trial
Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
Phase Phase 2 — COMPLETED
May 1, 2026
clinical_trial_readout
Results Pending: EMP-01 (Phase 2) — Completed 78d ago
Trial: Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
Sponsor: atai Therapeutics, Inc.
Phase: Phase 2 | Completed: 2026-02-12
Co